Loading...
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
PURPOSE: Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic warhead to the tumor, while maintaining...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3985381/ https://ncbi.nlm.nih.gov/pubmed/22382881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1852-8 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|